An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238). This is an ASCO Meeting Abstract from the 2019 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback